严重哮喘附加治疗试验中维持用药依从性评估不足导致检验效能降低与成本增加:系统综述与建模研究
报告依从性评估的试验其FEV1合并方差显著更低(0.144 L² vs 0.168 L²,p<0.0001),平均检验效能更高(59% vs 49%)。建模提示控制依从性变异可能将所需样本量减半。
要点
- 严重哮喘附加治疗试验中63%未报告维持治疗依从性评估,且无客观评估方法。
- 报告依从性评估的试验FEV1合并方差更低,检验效能更高(59% vs 49%)。
- 建模提示控制依从性变异可能将所需样本量减半。
核心结论
- 严重哮喘附加治疗试验中对维持吸入治疗依从性的监测不足,导致试验结局方差增大、检验效能不足,难以确定疗效。
研究设计与样本
- 利用数字化记录的依从性试验数据建模,估算统计效能与样本量的潜在改善。
主要发现
- 报告依从性评估的试验FEV1合并方差显著低于未评估者:s²=0.144 L² vs s²=0.168 L²,p<0.0001。
- 报告依从性评估的试验平均检验效能显著更高:59% vs 49%。
- 建模提示FEV1结局中高达50%的方差可归因于未检测的依从性变异。
关键数值与推荐
- 报告依从性评估的试验FEV1合并方差s²=0.144 L²,未评估者为s²=0.168 L²,p<0.0001。
- 报告依从性评估的试验平均检验效能59%,未评估者为49%。
- 建模提示控制依从性变异可能将所需样本量减半。
临床怎么用
- 在严重哮喘附加治疗试验中应纳入客观的维持治疗依从性评估,以降低结局方差、提高检验效能。
- 临床解读严重哮喘附加治疗试验结果时需考虑依从性评估不足对疗效判定的影响。
局限性
- 依从性对试验结局影响的估计基于数字化记录的依从性试验数据建模,可能受模型假设影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adherence to inhaled maintenance therapy in severe asthma is rarely adequately assessed, and its influence on trial outcomes is unknown. We systematically determined how adherence to maintenance therapy is assessed in clinical trials of "add-on" therapy for severe asthma. We model the improvement in trial power that could be achieved by accurately assessing adherence.A systematic search of six major databases identified randomised trials of add-on therapy for severe asthma. The relationship between measuring adherence and study outcomes was assessed. An estimate of potential improvements in statistical power and sample size was derived using digitally recorded adherence trial data.87 randomised controlled trials enrolling 22 173 participants were included. Adherence assessment was not reported in 67 trials (n=13 931, 63%). Studies that reported adherence used a range of self-report and subjective methods. None of the studies employed an objective assessment of adherence. Studies that reported adherence had a significantly reduced pooled variance in forced expiratory volume in 1 s (FEV1) compared to those that did not assess adherence: s2=0.144 L2 versus s2=0.168 L2, p<0.0001. Power to detect clinically relevant changes in FEV1 was significantly higher in trials that reported adherence assessment (mean power achieved 59% versus 49%). Modelling suggests that up to 50% of variance in FEV1 outcomes is attributable to undetected variations in adherence. Controlling for such variations could potentially halve the required sample size.Few trials of add-on therapy monitor adherence to maintenance inhaled therapy, resulting in a greater variance in trial outcomes and inadequate power for determining efficacy.
引用
- Mokoka MC, McDonnell MJ, MacHale E, et al. Inadequate assessment of adherence to maintenance medication leads to loss of power and increased costs in trials of severe asthma therapy: results from a systematic literature review and modelling study. Eur Respir J. 2019. PMID: 30846467. doi:10.1183/13993003.02161-2018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。